title: Effects of cisapride on ventricular repolarization in children.
abstract: Life-threatening ventricular dysrhythmias mainly attributed to QTc prolongation have been reported in adults and children who were using cisapride, a prokinetic agent that facilitates gastrointestinal motility. Recent adult and paediatric case reports have suggested an association of malignant ventricular dysrhythmias with administration of cisapride in conjunction with drugs that inhibit its cytochrome P-450 metabolism. Therefore, to analyse the time- and dose-related effects of cisapride on ventricular repolarization, we prospectively studied infants and children receiving cisapride with no concomitant medications. Standard 12-lead resting ECGs were obtained from 38 patients (mean age: 6.6 +/- 4.4 y) before the first dose of cisapride (0.8-1.2 mg/kg/d) therapy, and 3 d, 7 d and 1 mo after the first dose of continuing cisapride therapy. The corrected QT interval (QTc), dispersion of QT and QTc (QTD, QTcD) were calculated. Patients were divided into two groups according to dose of cisapride: Group 1 (n = 22) (0.8 mg/kg/d), Group 2 (n = 16) (1.2 mg/ kg/d). Data obtained from these patients were compared with a control group consisting of 372 normal children. No clinical adverse effects such as palpitations, presyncope or syncope were noted during the study. Baseline QTc, QTD and QTcD measurements of the study group were not different from those of the control group. Mean QTc values of the study group on days 7 and 30 of cisapride therapy were found to be significantly higher than those of the control group (p < 0.001 and <0.0001, respectively). Mean QTc values of the study group on days 7 and 30 of therapy were also significantly higher than those of baseline value (p < 0.01 and <0.001, respectively). Mean QTD and mean QTcD values that were recorded throughout the cisapride treatment in the study group were not found to be different from the baseline values and the values of the controls. Mean QTD and QTcD were also not found to be different between Groups 1 and 2. However, mean QTc was found to be more significantly increased from baseline at the first month of therapy in Group 2 (p < 0.05). The results of this study suggest that cisapride treatment cause prolongation of ventricular repolarization without causing increased heterogeneity of repolarization (QT dispersion). However, the clinical significance of this effect is unclear, because all the patients in this study group remained asymptomatic, without signs of dysrhythmia.
authors.affiliation: Department of Pediatric Cardiology, Ankara University Medical School, Turkey. tutor@dialup.ankara.edu.tr
authors.forename: H E
authors.initials: HE
authors.lastname: Tutar
authors.forename: A
authors.initials: A
authors.lastname: Kansu
authors.forename: A G
authors.initials: AG
authors.lastname: Kalayci
authors.forename: N
authors.initials: N
authors.lastname: Girgin
authors.forename: S
authors.initials: S
authors.lastname: Atalay
authors.forename: A
authors.initials: A
authors.lastname: Imamoğlu
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000293:Adolescent; D000328:Adult; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002648:Child; D002675:Child, Preschool; D020117:Cisapride / Q000009:adverse effects*; D003577:Cytochrome P-450 Enzyme System; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D008133:Long QT Syndrome / Q000139:chemically induced; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D005765:Gastrointestinal Agents; D003577:Cytochrome P-450 Enzyme System; D020117:Cisapride